ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1023

Fracture Risk Reduction with Romosozumab: Results of a Phase 3 Study in Postmenopausal Women with Osteoporosis

F Cosman1, DB Crittenden2, JD Adachi3, N Binkley4, E Czerwinski5, S Ferrari6, LC Hofbauer7, E Lau8, EM Lewiecki9, A Miyauchi10, CAF Zerbini11, CE Milmont2, L Chen2, J Maddox2, PD Meisner12, C Libanati12 and A Grauer2, 1Helen Hayes Hospital, West Haverstraw, and Columbia University, New York, NY, 2Amgen Inc., Thousand Oaks, CA, 3McMaster University, Hamilton, ON, Canada, 4University of Wisconsin–Madison Osteoporosis Clinical Center and Research Program, Madison, WI, 5Krakow Medical Center, Krakow, Poland, 6Geneva University Hospital, Geneva, Switzerland, 7Division of Endocrinology, Diabetes, and Bone Diseases, TU Dresden Medical Center, Dresden, Germany, 8Center for Clinical and Basic Research, Hong Kong, China, 9New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 10Miyauchi Medical Center, Osaka, Japan, 11Centro Paulista de Investigação Clinica, São Paulo, Brazil, 12UCB Pharma, Brussels, Belgium

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: clinical trials, fractures, osteo-anabolics, osteoporosis and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Session Title: Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:  Romosozumab (Romo) is an investigational bone-forming monoclonal antibody that binds sclerostin and has a dual effect, increasing bone formation and decreasing bone resorption. Here, we report results of the FRActure study in postmenopausal woMen with ostEoporosis (FRAME) (NCT01575834).

Methods:  This multicenter, randomized, double-blind, placebo-controlled study enrolled postmenopausal women aged 55 to 90 years with osteoporosis (BMD T-score ≤ –2.5 at the total hip or femoral neck). Subjects were randomized 1:1 to subcutaneous placebo (Pbo) or 210 mg Romo monthly for 12 months, followed by subcutaneous denosumab (DMAb) every 6 months for 12 months in both groups. The co-primary endpoints were subject incidence of new vertebral fracture through month (M) 12 and M24. Secondary endpoints included clinical (nonvertebral plus symptomatic vertebral) and nonvertebral fracture, and BMD.

Results:  A total of 7180 women (mean age 71 years, mean total hip T-score –2.5) were enrolled. At M12, Romo reduced new vertebral fracture, with a relative risk reduction (RRR) of 73% (subject incidence of fracture: 1.8% Pbo vs 0.5% Romo; P < 0.001). In subjects who received Romo in year 1, vertebral fracture risk reduction persisted through M24 after both groups transitioned to DMAb (2.5% Pbo/DMAb vs 0.6% Romo/DMAb; RRR 75%; P < 0.001). Romo reduced clinical fracture risk at M12 (2.5% Pbo vs 1.6% Romo; RRR 36%; P = 0.008). Nonvertebral fracture incidence through M12 was 2.1% for Pbo (lower than expected) vs 1.6% for Romo (RRR 25%; P = 0.096), with a similar risk reduction through M24 (Pbo/DMAb vs Romo/DMAb RRR 25%; nominal P = 0.029, adjusted P = 0.057). A preplanned analysis revealed a significant interaction between treatment and geographic region for nonvertebral fracture at M12 (P = 0.042). Nonvertebral fracture incidence in Central/Latin America was 1.2% for Pbo vs 1.5% for Romo, whereas a 42% RRR in nonvertebral fracture was observed in rest-of-world (P = 0.012). Compared to Pbo, Romo increased BMD by 12.7% and 5.8% at the lumbar spine and total hip, respectively, at M12 (P < 0.001). Adverse events were generally balanced between groups, with injection-site reactions in 2.9% of Pbo subjects and 5.2% of Romo subjects during year 1. One atypical femoral fracture and 2 osteonecrosis of the jaw events were positively adjudicated in the Romo group through M24.

Conclusion:  In postmenopausal women with osteoporosis, Romo 210 mg monthly was well tolerated and reduced vertebral and clinical fracture risk vs Pbo at M12; vertebral fracture risk reduction persisted in Romo subjects through M24 after both groups transitioned to DMAb. The sequence of Romo followed by DMAb may be a highly effective treatment for postmenopausal women with osteoporosis.


Disclosure: F. Cosman, Amgen, Eli Lilly, 2,Amgen, Eli Lilly, 8,Amgen, Eli Lilly, Merck, Radius, Sermonix, 5; D. Crittenden, Amgen, 3,Amgen, 1; J. Adachi, Amgen, Eli Lilly, Pfizer, 2,Amgen, Eli Lilly, 5,International Osteoporosis Foundation, Osteoporosis Canada, 6,Amgen, Eli Lilly, 8; N. Binkley, Amgen, GE Healthcare, Lilly, Merck, Opko Ireland, 2,Amgen, Astellas, Bristol-Myers Squibb, Lilly, Merck, Nestle, 5; E. Czerwinski, Amgen, 2,Amgen, 9; S. Ferrari, MSD, 2,Amgen, MSD, UCB, 5; L. Hofbauer, Amgen, Novartis, 2,Alexion, Amgen, Eli Lilly, Merck, UCB, 5; E. Lau, None; E. Lewiecki, Amgen, Merck, Lilly, 2,Amgen, Merck, Lilly, Shire, Alexion, 5,Shire, 8; A. Miyauchi, Amgen Astellas BioPharma K.K., 5; C. Zerbini, Pfizer, Lilly, Amgen, Merck, Sanofi, 2,Pfizer, Lilly, Sanofi, 5; C. Milmont, Amgen, 3,Amgen, 1; L. Chen, Amgen, 3,Amgen, 1; J. Maddox, Amgen, 3,Amgen, 1; P. Meisner, UCB Pharma, 3,UCB Pharma, 1; C. Libanati, UCB Pharma, 1,UCB Pharma, 3; A. Grauer, Amgen, 3,Amgen, 1.

To cite this abstract in AMA style:

Cosman F, Crittenden D, Adachi J, Binkley N, Czerwinski E, Ferrari S, Hofbauer L, Lau E, Lewiecki E, Miyauchi A, Zerbini C, Milmont C, Chen L, Maddox J, Meisner P, Libanati C, Grauer A. Fracture Risk Reduction with Romosozumab: Results of a Phase 3 Study in Postmenopausal Women with Osteoporosis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/fracture-risk-reduction-with-romosozumab-results-of-a-phase-3-study-in-postmenopausal-women-with-osteoporosis/. Accessed June 1, 2023.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fracture-risk-reduction-with-romosozumab-results-of-a-phase-3-study-in-postmenopausal-women-with-osteoporosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences